Detail akcie MABION online

Business Summary: Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Mabion SA revenues decreased 16% to PLN63.8M. Net income decreased 12% to PLN27.8M. Revenues reflect Sale of Products decrease of 15% to PLN61.4M, Leasing decrease of 35% to PLN1.5M. Net income also reflects General/Admin. Expense increase of 45% to PLN27.4M (expense), Interest Expense increase from PLN32K to PLN2.2M (expense), Legal Provisions & Litigation Expenses increase from PLN15K to PLN46K (expense).